RxDoctor Payments Data

Lawrence Lee, MD

Internal Medicine · Pelham, ALNPI 1063424935

Payments from drug & device makers

$8,574in general payments, 2019–2025

Across 495 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$911
  • AstraZeneca$757
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$576
  • Pfizer$570
  • Otsuka America Pharmaceutical, Inc.$460
  • Lilly USA, LLC$404
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$8,551100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,574 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$112,144
Medicare patients
319
Services billed
2,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban673$300,193
TrulicityDulaglutide169$169,927
IngrezzaValbenazine Tosylate35$156,079
XareltoRivaroxaban196$100,365
RexultiBrexpiprazole81$88,060
XifaxanRifaximin45$79,557
OzempicSemaglutide72$73,469
NuplazidPimavanserin Tartrate25$61,651
LinzessLinaclotide129$56,415
JardianceEmpagliflozin73$49,789
FarxigaDapagliflozin Propanediol101$48,558
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$45,826
Lacosamide98$43,737
MounjaroTirzepatide36$42,183
Pantoprazole Sodium877$38,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$570$300,193673 claims
Lilly USA, LLCTrulicity, Mounjaro$404$212,110205 claims
Johnson & JohnsonXarelto, Risperdal Consta$152$135,578213 claims
Otsuka America Pharmaceutical, Inc.Rexulti$460$88,06081 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$576$79,55745 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$369$79,161139 claims
Novo NordiskOzempic$374$73,46972 claims
Boehringer IngelheimJardiance, Combivent Respimat$140$66,008104 claims
AstraZenecaFarxiga, Breztri Aerosphere$757$62,512123 claims
Acadia Pharmaceuticals IncNuplazid$33$61,65125 claims
AbbVieLinzess$911$56,415129 claims
MerckJanuvia, Janumet$155$55,51375 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Pelham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →